The results from this clinical study suggest the importance of combined application of anti-CTLA-4 monoclonal antibody, anti-PD-1-PD-L1 monoclonal antibody, and radiotherapy, which activate the anti-tumor responses in multiple mechanisms. The gene discussed is CTLA4; the disease is neoplasm.